Abstracts Archive - Page 1011 of 2425 - ACR Meeting Abstracts

Abstract Number: 94 • 2018 ACR/ARHP Annual Meeting
Circulating Soluble MICA Is Associated to Lupus Nephritis and to a TLR/IFN-I Signature in T Cells in a Cohort of Adult SLE Patients
Maria Perez-Ferro¹, Fredeswinda I. Romero-Bueno¹, Cristina Serrano del Castillo², Raquel Largo³, Gabriel Herrero-Beaumont³ and Olga Sanchez-Pernaute⁴, ¹Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ²Immunology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ³Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ⁴Rheumatology Division. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: The MHC class I-related chain A (MICA) is a major ligand for the NKG2D receptor of NK and CD8 T cells. MICA expression at…
Abstract Number: 95 • 2018 ACR/ARHP Annual Meeting
Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis
Takashi Igawa¹, Kunihiro Ichinose¹, Masataka Umeda¹, Tomohiro Koga¹, Mizuna Eguchi², Momoko Okamoto², Yushiro Endo², Sousuke Tsuji², Ayuko Takatani¹, Toshimasa Shimizu¹, Shoichi Fukui¹, Remi Sumiyoshi², Shinya Kawashiri², Naoki Iwamoto¹, Mami Tamai¹, Hideki Nakamura¹, Tomoki Origuchi³, George C Tsokos⁴ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus(SLE) is multisystem disorder that is caused by tissue damage resulting from antibody and complement-fixing immune complex deposition. Lupus nephritis(LN) is frequent…
Abstract Number: 96 • 2018 ACR/ARHP Annual Meeting
The Liver X Receptor Modulates Inflammatory Cytokines Based on Lxrα Polymorphism in Monocyte-Derived Macrophages and Patients with Systemic Lupus Erythematosus
Chang-Hee Suh¹, Wook-Young Baek², Hyoun-Ah Kim³ and Ju-Yang Jung², ¹Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ²Ajou University School of Medicine, Suwon, Korea, Republic of (South), ³Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South)
Background/Purpose: Liver X receptors (LXRs) have emerged as important regulators of inflammatory gene expression. Previously, we had reported that an LXRα gene promoter polymorphism (-1830…
Abstract Number: 97 • 2018 ACR/ARHP Annual Meeting
Enhanced IFN-α Production By Plasmacytoid Dendritic Cells Is Associated with Increased Toll-like Receptor 7 Retention in the Lysosomes and Exosure to Type I IFN in Systemic Lupus Erythematosus
Goh Murayama¹, Asako Chiba², Ayako Makiyama², Ken Yamaji¹, Naoto Tamura¹ and Sachiko Miyake², ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Immunology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Type I interferon(IFN) appears to contribute to the development of systemic lupus erythematosus (SLE). Overexpression of type I IFN regulated genes has been reported…
Abstract Number: 98 • 2018 ACR/ARHP Annual Meeting
Presence of Apoptotic Microparticle Containing Immune Complexes in Asymptomatic ANA+ Individuals Despite the Absence of Inflammation
Carolina Muñoz-Grajales^1,2, Dennisse Bonilla¹, Ariana Karanxha¹, Dario Ferri^1,2, Earl Silverman³, Sindhu Johnson⁴, Arthur Bookman⁵, Zahi Touma^5,6 and Joan E. Wither^1,2,5,7, ¹Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Immunology, Department of Immunology, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁵Division of Rheumatology, University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Department of Medicine, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Currently, little is known about what distinguishes asymptomatic Anti-Nuclear Antibody (ANA) positive individuals (ANA+NS) who will progress to Systemic Lupus Erythematosus (SLE) from those…
Abstract Number: 99 • 2018 ACR/ARHP Annual Meeting
DC-Hil+ Myeloid-Derived Suppressor Cells Are Elevated in the Peripheral Blood and Lesional Skin of Cutaneous Lupus Patients
Stephanie Florez-Pollack¹, Lin-chiang Tseng¹, Masato Kobayashi¹, Gregory Hosler^1,2, Kiyoshi Ariizumi¹ and Benjamin F. Chong¹, ¹Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ²Propath, Dallas, TX
Background/Purpose: Myeloid derived suppressor cells (MDSCs) are major T cell suppressors, and their dysfunction has been implicated in the pathophysiology of autoimmune diseases. MDSCs suppress…
Abstract Number: 100 • 2018 ACR/ARHP Annual Meeting
Glycosphingolipids and Proteins in Urine Exosomes: Potential Biomarkers of Lupus Nephritis
Tamara K. Nowling¹, Jessalyn Rodgers¹, Jim C. Oates², Michael Janech³ and Richard Drake⁴, ¹Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Medicine/Nephrology, Medical University of South Carolina, Charleston, SC, ⁴Pharmacology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Exosomes, extracellular vesicles that are abundant in human urine and contain proteins from renal cells, are a potential source of biomarkers of renal disease…
Abstract Number: 101 • 2018 ACR/ARHP Annual Meeting
Regulation of Monocyte Function By Epstein Barr Virus Interleukin-10 (vIL10) in Systemic Lupus Erythematosus
Neelakshi R. Jog¹, Eliza Chakravarty¹, Joel M. Guthridge¹ and Judith A. James^2,3, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterized by periods of elevated and suppressed disease activity. Epstein Barr Virus (EBV) has been…
Abstract Number: 102 • 2018 ACR/ARHP Annual Meeting
Estrogen Controls the Expression of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in Human T Lymphocytes Via Transcriptional and Post-Transcriptional Mechanisms
Julian F. Oviedo¹, Elena N. Cravens¹ and Vaishali R. Moulton^2,3, ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Medicine/Rheumatology, Boston, MA, ²Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ³Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic debilitating autoimmune disease that primarily afflicts women in the childbearing years. Female hormones especially estrogen are implicated…
Abstract Number: 103 • 2018 ACR/ARHP Annual Meeting
Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- double Negative (DN) T Cell Subsets in Lupus-Prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement
Yi Li¹, Hao Li², Vasileios C. Kyttaris³ and George C Tsokos⁴, ¹Medicine, BIDMC, Boston, MA, ²Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA, ⁴Division of Rheumatology, Department of Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA
Background/Purpose: We have previously shown that DN T cells are expanded in both lupus-prone mice and patients with SLE and we have demonstrated that this…
Abstract Number: 104 • 2018 ACR/ARHP Annual Meeting
Identification of a Gut Pathobiont Immunostimulatory Lipoglycan Antigen Linked to Lupus Nephritis
Gregg Silverman¹, Nicolas Gisch², Aidana Omarbekova³ and Doua F. Azzouz⁴, ¹Department of Medicine, New York University School of Medicine, New York, NY, ²Research Center Borstel, Schleswig-Holstein, Germany, ³New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY
Background/Purpose: A transmissible agent has long been suspected in SLE. In a discovery cohort we found that,compared with healthy subjects, Lupus patients had a five-fold…
Abstract Number: 105 • 2018 ACR/ARHP Annual Meeting
Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials
Majid Zeidi^1,2, Krisha Desai^3,4, Hee Joo Kim^3,4,5 and Victoria P. Werth^3,4, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Department of Dermatology, Gachon Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea, Republic of (South)
Background/Purpose: Two major therapies for cutaneous lupus erythematosus (CLE) are the antimalarials, hydroxychloroquine (HCQ) and quinacrine (QC). HCQ is often the first-line therapy for CLE,…
Abstract Number: 106 • 2018 ACR/ARHP Annual Meeting
Highly Elevated Levels of Anti-Mitochondrial Antibodies in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Richard Moore¹ and Christian Lood², ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: We recently described the phenomenon in systemic lupus erythematosus (SLE) in which mitochondria are extruded into the extracellular space during formation of neutrophil extracellular…
Abstract Number: 107 • 2018 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants, Renal Histopathology, and Prognosis in African American SLE Nephritis Patients: A Cohort Study
Ashira Blazer¹, Ming Wu², Nancyanne Schmidt³, Alana Engelbrecht⁴, Feng-Xia Liang⁵, Robert M. Clancy⁶, Jill P. Buyon⁷ and H. Michael Belmont⁸, ¹Internal Medicine Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Pathology, New York University, New York, NY, ³Internal Medicine, New York University School of Medicine, New York, NY, ⁴Rheumatology, NYU Langone Health, New York, NY, ⁵Office of Science and Research, New York University School of Medicine, New York, NY, ⁶Colton Center for Autoimmunity, New York University, New York, NY, ⁷Rheumatology, NYU School of Medicine, New York, NY, ⁸Division of Rheumatology, New York University, New York, NY
Background/Purpose: Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2, associate with CKD in African Americans (AA) and are evolutionarily preserved due to improved infectious…
Abstract Number: 108 • 2018 ACR/ARHP Annual Meeting
Sex-Specific Expression of CXorf21 Provide Molecular Explanation for the Fundamental Difference in Male and Female Immune Response: An Explanation for Female-Bias SLE Pathogenesis
R. Hal Scofield¹, Valerie M Harris², Biji T. Kurien³ and Kristi A. Koelsch⁴, ¹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Section of Endocrinology and Diabetes, University of Oklahoma Health Sciences Center, Okalahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is complex autoimmune disorders characterized by B cell hyperactivity resulting in autoantibody and cytokine production. Approximately 90% of patients are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].